Recombinant arylsulfatase B
Galsulfase
Brand names: Naglazyme
Adult dose
Dose: 1 mg/kg IV weekly over 4h with pre-medication
Route: IV
Frequency: weekly
Clinical pearls
- Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome)
- Pre-medicate with antihistamine ± antipyretic
Contraindications
- Severe hypersensitivity to galsulfase
Side effects
- Infusion reactions
- Anaphylaxis
- Pyrexia
- Headache
- Antibody development
Monitoring
- Infusion observations
- Antibody titres
Reference: BNF; SmPC; https://bnf.nice.org.uk/drugs/galsulfase/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016